Loading clinical trials...

Russian Registry of Patients With nAMD | Clinical Trials | Clareo Health

TERMINATED

Russian Registry of Patients With nAMD

Russian Registry of Patients With Neovascular Age-Related Macular Degeneration (nAMD)

NCT04935411•Novartis Pharmaceuticals

View on ClinicalTrials.gov

Summary

A three-year, non-randomized, observational, multicenter prospective nAMD study - patient registry.

Detailed Description

The registry is a structured system which uses observational study methods for systematic collection of data on health condition in the specific patient population. Real world clinical practice data will be collected. Patients will not undergo any additional examinations or procedures that are outside of the standard clinical practice

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Age \> to 18 years
•Male or female patients diagnosed with nAMD (with or without previous treatment for nAMD including but not limited to PDT, laser coagulation, vitamins, retinolamine, emoxipine, anti-VEGF therapy or any surgery for nAMD).
•Willing and able to provide informed written consent personally or by legal proxy
•The patient is simultaneously participating in a different nAMD therapy study.

Locations (1)

Novartis Investigative Site

Novosibirsk, Russia

Key Dates

Start Date

December 20, 2020

Primary Completion Date

December 5, 2022

Completion Date

December 5, 2022

Last Updated

August 7, 2025

Enrollment

2,665

ACTUAL participants

Conditions

Neovascular Age-Related Macular Degeneration

Interventions

nAMD

OTHER

A Study of the Efficacy, Safety, and Pharmacokinetics (PK) of the Port Delivery System With Ranibizumab (PDS) in Chinese Participants With Neovascular Age-related Macular Degeneration (nAMD)

NCT05562947

Neovascular Age-related Macular DegenerationnAMD

View study

RECRUITINGPHASE3

Home OCT-Guided Treatment Versus Treat and Extend for the Management of Neovascular AMD

NCT05904028

Neovascular Age-related Macular Degeneration

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: August 7, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Russian Registry of Patients With nAMD

Inclusion Criteria

A Study of the Efficacy, Safety, and Pharmacokinetics (PK) of the Port Delivery System With Ranibizumab (PDS) in Chinese Participants With Neovascular Age-related Macular Degeneration (nAMD)

Home OCT-Guided Treatment Versus Treat and Extend for the Management of Neovascular AMD

A Clinical Study Evaluating the Safety and Efficacy of SKG0106 in Patients With Neovascular Age-related Macular Degeneration (nAMD)

Gene Therapy(FT-003) for Wet AMD

Long-term Follow-Up Study of RGX-314 and Fellow Eye Substudy

A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products